VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus

Immunology

Volumn 142, Issue 4, 2014, Pages 594-602

  Fagone, Paolo ^a   Muthumani, Karuppiah ^b   Mangano, Katia ^a   Magro, Gaetano ^a   Meroni, Pier Luigi ^c   Kim, Joseph J ^d   Sardesai, Niranjan Y ^d   Weiner, David B ^b   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d Inovio Pharmaceuticals Inc   (United States)

Author keywords

Autoimmunity; Bioinformatics; Cell activation

Indexed keywords

3 PHENYL 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID; IMMUNOMODULATING AGENT; ISOXAZOLINE DERIVATIVE; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VGX 1027;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROARRAY ANALYSIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNITY; BIOINFORMATICS; CELL ACTIVATION;

ACETATES; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; OXAZOLES; TOLL-LIKE RECEPTOR 4;

EID: 84904048838     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12267     Document Type: Article

References (26)

1. Stojanovic I, Cuzzocrea S, Mangano K et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immunol 2007; 123:311-23.
2. Stosic-Grujicic S, Cvetkovic I, Mangano K et al. A potent immunomodulatory compound, (S, R)-3-Phenyl-4, 5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther 2007; 320:1038-49.
3. + CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur J Pharmacol 2008; 586:313-21.
4. Medina I, Carbonell J, Pulido L et al. Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res 2010; 38:W210-3.
5. Saeed AI, Sharov V, White J et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34:374-8.
6. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
7. Nicoletti F, Di Marco R, Zaccone P et al. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur J Immunol 2000; 30:438-47.
8. Kanehisa M, Goto S, Sato Y et al. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012; 40:D109-14.
9. Malmberg KJ, Michaëlsson J, Parham P et al. Killer cell immunoglobulin-like receptor workshop: insights into evolution, genetics, function, and translation. Immunity 2011; 35:653-7.
10. Whitby FG, Masters EI, Kramer L et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000; 408:115-20.
11. Bonnal S, Vigevani L, Valcárcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012; 11:847-59.
12. Zhao XF, Nowak NJ, Shows TB et al. MAGOH interacts with a novel RNA-binding protein. Genomics 2000; 63:145-8.
13. Mann SS, Pettenati MJ, von Kap-herr C et al. Reassignment of peptidyl prolyl isomerase-like 1 gene (PPIL1) to human chromosome region 6p21.1 by radiation hybrid mapping and fluorescence in situ hybridization. Cytogenet Cell Genet 1999; 83:228-9.
14. Ingelfinger D, Arndt-Jovin DJ, Luhrmann R et al. The human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl in distinct cytoplasmic foci. RNA 2003; 8:1489-501.
15. Virbasius CM, Wagner S, Green MR. A human nuclear-localized chaperone that regulates dimerization, DNA binding, and transcriptional activity of bZIP proteins. Mol Cell 1999; 4:219-28.
16. Sui M, Lin Q, Xu Z et al. Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol 2013; 33:378-87.
17. Zhang L, Bertucci AM, Ramsey-Goldman R et al. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol 2013; 149:365-78.
18. Henriques A, Inês L, Carvalheiro T et al. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int 2012; 32:863-9.
19. + monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis 2007; 50:47-58.
20. 1 mice. J Exp Med 1994; 179:305-10.
21. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009; 32:223-30.
22. Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy Immunol 2003; 25:105-12.
23. Lutalo PM, D'Cruz DP. Belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther 2012; 12:957-63.
24. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181:839-44.
25. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 1999; 48:255-61.
26. González-Amaro R, Portales-Pérez D, Baranda L et al. Role of IL-10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus. J Autoimmun 1998; 11:395-402.